Drug name(s)
Tasigna® Danziten™ Cavhanza™ NilotinibIndications and usage
Tasigna® is FDA approved for the treatment of
- Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
- Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.
- Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.
Danziten™ is FDA approved for the treatment of
- Adults who have been newly diagnosed with a certain type of leukemia called Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
- Adults with chronic phase Ph+ CML or accelerated phase Ph+ CML who:
- Are no longer benefiting from other treatments, including imatinib (Gleevec), or
- Have taken other treatments, including imatinib (Gleevec), and cannot tolerate them.
Cavhanza™ is FDA approved for the treatment of
- Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
- Adults with CP Ph+ CML or accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy.
Side effects needing medical attention
Irregularity in heartbeat; fainting; unexplained bleeding or bruising; blood in urine or stool; unexplained weakness; yellow skin and eyes; shortness of breath; swelling of hands, ankles, feet, or face; joint pain; sudden stomach area pain with nausea and vomiting; fever; low blood count; rash; nausea; cough; headache; itching; tiredness; diarrhea; constipation; night sweats; the common cold.